ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Gene Therapy

Bayer hands control of Casebia to Crispr Therapeutics

by Ryan Cross
October 26, 2019 | APPEARED IN VOLUME 97, ISSUE 42

 

Bayer and Crispr Therapeutics teamed up in December 2015 to launch Casebia Therapeutics to develop gene-editing therapies for blood, eye, and heart diseases. Bayer pledged $300 million to the start-up, and Crispr pitched in $35 million. Bayer now plans to give Crispr full control of Casebia, although it still has rights to opt into two of the firm’s programs. Casebia is developing gene-editing therapies for hemophilia, multiple genetic forms of blindness, and a rare autoimmune disorder.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment